Charity Annual Report and Accounts 2021-22

What we have achieved

To invest in the capital programme and enhance the hospital environment

In December 2021 we opened The Christie at Macclesfield. The charity has released £23m over the last three years for this much needed and anticipated facility. It has brought Christie cancer care closer to home for patients in Cheshire, High Peak and North Staffordshire. This facility is now transforming cancer care, delivering local specialist access to chemotherapy and radiotherapy, holistic support and information services, outpatient care, palliative care, counselling and complementary therapy and a wider range of clinical trials than at previously offered. The £26 million development is equipped with state-of-the-art radiotherapy treatment machines, a CT scanner and 18 treatment chairs. It will provide 46,000 patient appointments and visits each year and is the third in a network of local Christie radiotherapy centres where patients can access Christie treatment closer to home.

This year we released the final funds for this build which totalled £15,485,488.

The Christie cancer centre in Macclesfield

To invest funds to improve the quality and quantity of clinical research

Investments in infrastructure posts has also helped to facilitate an increase in both commercial and non-commercial trial activity and income. The number of active trials has increased from 649 to 718 and patient recruitment for trials has increased from 2,452 to 3,545. We are also funding an exciting new project called The Academy of Surgical Oncology. We will fund this over the next three years. With the new academy we will be able to carry out surgical trials which is something that very few cancer centres in the UK do now. We will lead the way in this unique type of surgical clinical trial on a national and global scale with huge potential. As well as surgical trials, the Academy of Surgical Oncology will also

This year the charity invested over £1.7m towards research, supporting early-phase clinical trials along with several posts as part of the academic investment plan, supporting the Manchester Cancer Research Centre. This is an unprecedented global recruitment drive to bring up to 20 of the world’s leading cancer experts and their teams to Manchester. The charity provides pump-prime funding to enable these plans to be realised. By appointing these experts, the Trust is able to strengthen its experience in experimental cancer treatments, radiotherapy-related research and discovery research in tumour-specific themes.

11